XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 170 Months Ended
Sep. 30, 2023
Nov. 30, 2009
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2023
License agreements            
Revenues     $ 3,695,649 $ 3,394,635 $ 2,986,267  
United States            
License agreements            
Revenues     3,500,000 3,200,000 2,900,000  
JAKAFI            
License agreements            
Revenues     2,593,732 2,409,225 2,134,508  
Novartis            
License agreements            
Revenues     5,000 60,000 0  
Novartis | Development Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 157,000
Novartis | Development Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 174,000        
Novartis | Regulatory Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone $ 5,000         345,000
Novartis | Regulatory Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   495,000        
Novartis | Commercialization Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           200,000
Novartis | Commercialization Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   500,000        
Novartis | GVHD | Development and Regulatory Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 75,000        
Novartis | JAKAVI            
License agreements            
Revenues     $ 367,600 331,600 338,000  
Novartis | JAKAVI | Minimum            
License agreements            
Royalty payments on future global net sales     12.00%      
Novartis | JAKAVI | Maximum            
License agreements            
Royalty payments on future global net sales     14.00%      
Novartis | JAKAFI | United States            
License agreements            
Revenues     $ 122,100 113,100 99,600  
Royalties payable     375,600 253,500   $ 375,600
Novartis | TABRECTA            
License agreements            
Revenues     $ 17,800 $ 15,400 $ 10,400